News

Tiffani Botts Massey, PA-C, Florida Society of Dermatology PAs President Elect, and Heather Gates, PA-C, the organization's current president, preview the upcoming conference.

The Lancet data is the primary publication of bimekizumab results from BE HEARD I and BE HEARD II.

Scores for erythema, dryness, quality of life, and aesthetic improvement were all markedly improved in patients using tranexamic acid versus traditional therapy alone.

A new acne-specific HRQoL questionnaire developed in Europe could help to create more comprehensive, individualized treatment plans.

The new action date is December 29, 2024.

While MMS is recognized as the gold standard for skin cancer treatment, numerous challenges still hinder widespread adoption and practice.

VYNE Therapeutics' Iain Stuart, PhD, spoke with Dermatology Times to discuss recent phase 1 and pre-clinical data for VYN201 for vitiligo.

Researchers from NYU Langone recently published a study clarifying the role of HIF-1-alpha in inflammation and psoriasis, which has been unclear until now.

This month's Legal Eagle column examines if patients have a legal property right to health care, given public funding of medical education.

A study out of Japan found some biologics used to treat psoriasis may require higher dose escalation than others.

Andrew Baker, MBA, MPAS, PA-C, discusses his role in skin cancer detection and advice for PAs interested in skin surgeries and Mohs closures.

Ayesha Patrick, the founder of Sistas With Psoriasis, spoke with Dermatology Times about her involvement in AbbVie's Clearly Me campaign.

A large amount of studies included in the review centered around the use of botulinum toxin in these indications.

Some states offer great homestead protection, but most provide an inadequate shield. Learn how to protect your greatest assets.

A 5-expert panel continues their conversation on atopic dermatitis, discussing patient-centered care and key takeaways.

Results of a recent study show RECAP's impact on adult Asian patients with AD.

This week’s collection of the latest dermatologic studies includes case reports of onychocytic matricoma, congenital triangular alopecia treated with 5% topical minoxidil, systemic therapy usage in vulvar lichen sclerosus and vulvovaginal lichen planus, and dose escalation of interleukin inhibitors in Japanese patients with psoriasis.

Care Messenger helps to expand care delivery and respond to growing patient needs without placing additional strain on clinicians.

In recognition of Skin Cancer Awareness Month, Dermatology Times is reviewing research and strides in skin cancer treatment over the last decade.

Discover pearls on caring for patients with STDs, using dermatopathology in SOC, managing inflammatory skin conditions in women, and ensuring patients are able to access care needed.

Click here to read more and answer our quiz questions in recognition of Skin Cancer Awareness Month.

Keep up with the latest headlines in dermatology from the past week, including Johnson & Johnson's acquisition of Proteologix, a review of sunscreen approvals and efficacy, and more.

In case you missed it, this week we had news about roflumilast foam's efficacy in diverse hair types of seborrheic dermatitis, Lindus Health's new partnership to evaluate a benzoyl peroxide alternative, sonelokimab advancing to phase 3 for HS, and more.

Scassellati Sforzolini discusses the significance of Galderma’s nemolizumab receiving 4 additional filing acceptances for prurigo nodularis and atopic dermatitis.

Clearly Me uses portraiture to spotlight the journeys of psoriasis patients Katie Lowes, DaQuane Cherry, Ayesha Patrick, and Joanna “JoJo” Pomerantz.

It is important dermatologists learn to recognize the clinical findings of dermatophytomas and distinguish them from other onychomycosis subtypes because the recommended treatments differ.

Earlier this week, we shared our second Skin Cancer Awareness Month quiz. Review the answers and your responses below.

Researchers reviewed research into the medical and toxicological viewpoints of tattooing the skin from the past decade.

A recent study spotlights an opportunity for interdisciplinary collaboration between dermatologists and orthodontists.

VELA is the first phase 3 hidradenitis suppurativa trial to evaluate HiSCR75 as the primary end point.